Biogen Idec (BIIB)
Add to Watchlists Create an Alert
232.77
+1.44 +0.62%
NASDAQ
May 22, 4:59PM
BATS Real time
Currency in USD
Biogen Idec Free Cash Flow:
145.65M for March 31, 2013Biogen Idec Historical Free Cash Flow Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 145.65M |
| Dec. 31, 2012 | 432.24M |
| Sept. 30, 2012 | 483.72M |
| June 30, 2012 | 562.68M |
| March 31, 2012 | 140.07M |
| Dec. 31, 2011 | 359.38M |
| Sept. 30, 2011 | 519.17M |
| June 30, 2011 | 375.58M |
| March 31, 2011 | 221.44M |
| Dec. 31, 2010 | 382.22M |
| Sept. 30, 2010 | 389.28M |
| June 30, 2010 | 381.43M |
| March 31, 2010 | 298.69M |
| Dec. 31, 2009 | 223.82M |
| Sept. 30, 2009 | 227.85M |
| June 30, 2009 | 193.87M |
| March 31, 2009 | 263.71M |
| Dec. 31, 2008 | 353.25M |
| Sept. 30, 2008 | 447.32M |
| June 30, 2008 | 204.96M |
| March 31, 2008 | Go Pro |
About Free Cash Flow
Free cash flow is the amount of cash generated by a business that is available for distribution among its security holders. Security holders include debt holders, equity holders, preferred stock holders, and convertible security holders. Specifically, free cash flow is used to pay dividends, make acquisitions, develop new products, invest in new property, plant and equipment, pay interest expenses, and reduce debt.
According to many investors, free cash flow is the best indication of a company's ability to generate cash.
Learn More
BIIB Free Cash Flow Benchmarks
| Companies | |
|---|---|
| Elan | -28.50M |
| Novartis | 1.178B |
| Celgene Corporation | 341.20M |
BIIB Free Cash Flow Rankings
| Overall |
95th percentile 393 of 8005 |
| Sector |
94th percentile 40 of 686 in Healthcare |
| Industry |
97th percentile 5 of 248 in Biotechnology |
BIIB Free Cash Flow Range, Past 5 Years
| Minimum | 140.07M | Mar 2012 |
| Maximum | 562.68M | Jun 2012 |
| Average | 330.32M |
